Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

Firouzabadi, Negar; Raeesi, Roshanak; Zomorrodian, Kamiar; Bahramali, Ehsan; Yavarian, Ilnaz

doi:10.18433/j3w31f

Cited by 12 publications

(9 citation statements)

References 43 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study by Crowley et al showed lack of association between the functional polymorphism of G1165C and response to citalopram in depressed patients [28]. Another study carried out by Firouzabadi et al examining the effect of the same polymorphism in response to sertraline suggested that the patients who carried CC genotype responded five times more to sertraline in comparison with other variants and carriers of C allele responded three times more to sertraline than patients with the G allele [29]. According to our knowledge, role of G1165C polymorphism in efficacy of response to fluoxetine in a set of newly diagnosed Iranian MDD patients has not been conducted to date.…”

Section: Discussionmentioning

confidence: 99%

Association study of the beta-adrenergic receptor genetic variant Gly389Arg and fluoxetine response in major depression

Firouzabadi

Asadpour

Zomorrodian

2020

GMJ

Self Cite

View full text Add to dashboard Cite

Background: Pharmacogenetics has proven role in the treatment of different illnesses. Patients with special genotypes may achieve a better response to a specific drug. On the other hand, genetic parameters markedly contribute to the development of major depressive disorder (MDD). The significance of adrenergic system compartments in cognition and behavior, and their role in etiology of depression denote that adrenergic receptors beta gene polymorphism(s) might also have an association with drug response. Thus this study aims to evaluate the association between β1AR gene polymorphisms, G1165C, Arg389Gly and response to fluoxetine in MDD patients. Materials and Methods: Among different antidepressants, we focused on fluoxetine as it is prescribed frequently in MDD and belongs to one of the most efficient antidepressant categories with minimum side effects. MDD was diagnosed at study entry using DSM-IV criteria. One hundred and one new MDD patients were treated with fluoxetine for a period of 6 weeks. A 50% decrease in Hamilton Rating Scale for Depression (HRSD) was considered as response to treatment. Genotyping of G1165C polymorphism was performed by PCR-RFLP method. Results: Results of the study indicated no significant relationship between β1AR polymorphism and the patient’s response to fluoxetine neither at genotypic nor allelic level (P=0.568). Conclusion: Our study did not support the hypothesis of involvement of β1AR Arg389Gly polymorphism and response to fluoxetine in MDD patients. [GMJ.2020;9:e1781]

show abstract

Section: Discussionmentioning

confidence: 99%

Association study of the beta-adrenergic receptor genetic variant Gly389Arg and fluoxetine response in major depression

Firouzabadi

Asadpour

Zomorrodian

2020

GMJ

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a means of targeted treatment and personalized medicine, pharmacogenetics has currently drawn a lot of attention in many neurologic and psychiatric diseases (36)(37)(38)(39)(40). Although many studies have focused on the contribution of genetic factors in autism (41,42), their role as therapeutic elements stays illusive.…”

Section: Discussionmentioning

confidence: 99%

DRD3 Ser9Gly Polymorphism and Its Influence on Risperidone Response in Autistic Children

2017

Self Cite

View full text Add to dashboard Cite

-PURPOSE:Autism, a neuropsychiatric illness, is a complex ailment of mainly indefinite cause. Although precise pathophysiological mechanism is unclear but the role of genetics is undeniable therefore pharmacogenetics may assist to a better management of symptoms. Risperidone is widely used in autism. Considering the significance of dopaminergic system in psychological and neurological diseases and its association with autism, the hypothesis that genetic variant of dopamine receptor (DRD3), Ser9Gly (rs6280), may influence treatment of autism may be assumed. METHOD: In the present study, 56 autistic Persian children within the age range of 2.5 to 14 years were included. Diagnosis of autism was based on DSM-V criteria and the severity degree was measured by ABC-C checklists at base line and after 8 weeks of treatment with risperidone. Based on their scores patients were categorized as responsive and non-responsive groups. DRD3 Ser9Gly (rs6280) was determined by PCR-RFLP. RESULTS: Carriers of Gly allele as well as carriers of Gly/Gly and Ser/Gly genotypes showed significantly better response to risperidone compared with carriers of Ser allele and Ser/Ser genotype (P=0.027; OR= 4.18; 95%CI=1.16-15.03 and P=0.014; OR=6.825; 95%CI=1.36-34.13). CONCLUSION: Our results advocate the possible influence of genetic variation of DRD3 in clinical response to antipsychotics like risperidone in autistic individuals.

show abstract

“…The genetic variation of beta-1 adrenoceptors might influence clinical response to a specific antidepressant. A clinical study discerned the influence of the G1165C polymorphism in the beta-1 adrenoceptor gene on individual differences in response to sertraline, and it was found that CC genotype-carrying individuals responded five times more to sertraline compared to other variants and that the C allele carriers responded three times more to sertraline than patients with the G allele [ 63 ]. Interestingly, the antidepressant-promoting effect of polymorphism in the beta-1 adrenoceptor gene was not observed in patients who received repeated treatment with fluoxetine, one of the most frequently prescribed antidepressants [ 64 ].…”

Section: Functional Role Of Beta-adrenergic Receptors In Depression A...mentioning

confidence: 99%

The Role of Beta-Adrenergic Receptors in Depression and Resilience

et al. 2022

View full text Add to dashboard Cite

Norepinephrine is a catecholamine neurotransmitter that has been extensively implicated in the neurobiology of major depressive disorder (MDD). An accumulating body of evidence indicates that investigations into the action of norepinephrine at the synaptic/receptor level hold high potential for a better understanding of MDD neuropathology and introduce possibilities for developing novel treatments for depression. In this review article, we discuss recent advances in depression neuropathology and the effects of antidepressant medications based on preclinical and clinical studies related to beta-adrenergic receptor subtypes. We also highlight a beta-3 adrenergic receptor-involved mechanism that promotes stress resilience, through which antidepressant efficacy is achieved in both rodent models for depression and patients with major depression—an alternative therapeutic strategy that is conceptually different from the typical therapeutic approach in which treatment efficacy is achieved by reversing pathological alterations rather than by enhancing a good mechanism such as natural resilience. Altogether, in this review, we systematically describe the role of beta-adrenergic receptors in depression and stress resilience and provide a new avenue for developing a conceptually innovative treatment for depression.

show abstract

Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

Cited by 12 publications

References 43 publications

Association study of the beta-adrenergic receptor genetic variant Gly389Arg and fluoxetine response in major depression

Association study of the beta-adrenergic receptor genetic variant Gly389Arg and fluoxetine response in major depression

DRD3 Ser9Gly Polymorphism and Its Influence on Risperidone Response in Autistic Children

The Role of Beta-Adrenergic Receptors in Depression and Resilience

Contact Info

Product

Resources

About